Your session is about to expire
← Back to Search
Potassium Channel Activator
Diazoxide for Diabetes Mellitus
Phase 2
Waitlist Available
Led By Meredith Hawkins, M.D., M.S.
Research Sponsored by Albert Einstein College of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Negative drug screen
Not suffering from proliferative retinopathy, significant diabetic renal disease or severe neuropathy (including cardiovascular and gastrointestinal autonomic dysfunction)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 hours post dosing, 4 hours post dosing
Awards & highlights
Study Summary
This trial will study whether people with type 2 diabetes have impaired activation of certain brain centers, which may contribute to their condition.
Eligible Conditions
- Diabetes Mellitus
- High Blood Sugar
- Type 2 Diabetes
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 hours post dosing, 4 hours post dosing
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 hours post dosing, 4 hours post dosing
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in Arterial Spin Labeling (ASL) signal measured using 3T MRI from 2 hours post dosing to 4 hours post dosing
Change in Arterial Spin Labeling (ASL) signal measured using 3T MRI from Baseline to 2 hours post dosing
Trial Design
4Treatment groups
Experimental Treatment
Placebo Group
Group I: T2D (Diazoxide)Experimental Treatment1 Intervention
Proglycem, oral suspension (4-7 mg/kg). Type 2 diabetic (T2D) participants will receive diazoxide between MRI scans.
Group II: Healthy (Diazoxide)Experimental Treatment1 Intervention
Proglycem, oral suspension (4-7 mg/kg). Healthy participants will receive diazoxide between MRI scans.
Group III: T2D (Placebo)Placebo Group1 Intervention
Taste-matched placebo. T2D participants will receive placebo between MRI scans.
Group IV: Healthy (Placebo)Placebo Group1 Intervention
Taste-matched placebo. Healthy participants will receive placebo between MRI scans.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Diazoxide
2006
Completed Phase 4
~80
Find a Location
Who is running the clinical trial?
Albert Einstein College of MedicineLead Sponsor
285 Previous Clinical Trials
11,854,618 Total Patients Enrolled
17 Trials studying Diabetes Mellitus
4,715 Patients Enrolled for Diabetes Mellitus
National Institutes of Health (NIH)NIH
2,679 Previous Clinical Trials
6,910,658 Total Patients Enrolled
88 Trials studying Diabetes Mellitus
250,392 Patients Enrolled for Diabetes Mellitus
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,338 Previous Clinical Trials
4,314,175 Total Patients Enrolled
471 Trials studying Diabetes Mellitus
2,412,072 Patients Enrolled for Diabetes Mellitus
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger